Your browser is no longer supported. Please, upgrade your browser.
AEMD Aethlon Medical, Inc. weekly Stock Chart
Aethlon Medical, Inc.
Index- P/E- EPS (ttm)-4.51 Insider Own1.70% Shs Outstand2.89M Perf Week2.44%
Market Cap11.50M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float8.89M Perf Month-11.89%
Income-6.20M PEG- EPS next Q-0.16 Inst Own14.40% Short Float2.62% Perf Quarter-48.57%
Sales0.50M P/S23.01 EPS this Y25.90% Inst Trans152.00% Short Ratio0.38 Perf Half Y-65.20%
Book/sh1.36 P/B0.93 EPS next Y90.00% ROA-191.50% Target Price- Perf Year-85.13%
Cash/sh0.45 P/C2.81 EPS next 5Y- ROE-325.80% 52W Range0.76 - 9.00 Perf YTD30.84%
Dividend- P/FCF- EPS past 5Y37.00% ROI-176.40% 52W High-86.00% Beta0.74
Dividend %- Quick Ratio5.30 Sales past 5Y-32.40% Gross Margin- 52W Low64.92% ATR0.10
Employees6 Current Ratio5.30 Sales Q/Q- Oper. Margin- RSI (14)40.37 Volatility7.06% 7.41%
OptionableNo Debt/Eq0.00 EPS Q/Q83.00% Profit Margin- Rel Volume0.16 Prev Close1.23
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume619.86K Price1.26
Recom2.00 SMA20-6.46% SMA50-10.64% SMA200-53.68% Volume102,094 Change2.44%
Mar-24-20 08:58AM  Aethlon Announces Issuance of European Patent for the Hemopurifier® in Cancer PR Newswire -8.78%
Mar-06-20 12:08PM  AEMD: Coronavirus 2019 (COVID-19) Could Represent New Opportunity for AEMD Zacks Small Cap Research +7.62%
Feb-25-20 03:25PM  18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -17.55%
Feb-24-20 10:22AM  Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical Stock Expires PR Newswire -5.04%
Feb-17-20 01:37PM  Edited Transcript of AEMD earnings conference call or presentation 10-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-13-20 05:35AM  Investors Who Bought Aethlon Medical (NASDAQ:AEMD) Shares Five Years Ago Are Now Down 98% Simply Wall St.
Feb-10-20 04:15PM  Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update PR Newswire
09:01AM  Securities and Exchange Commission (SEC) Order for Halt in trading of Aethlon Medical (NASDAQ:AEMD) Stock PR Newswire
Feb-06-20 08:01AM  Aethlon Medical To Release Third Quarter Financial Results and Host Conference Call on February 10, 2020 PR Newswire
Jan-23-20 01:02PM  13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak Benzinga
09:51AM  The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech Zacks
Jan-22-20 02:28PM  Health stocks reverse coronavirus gains as one analyst says the market is overreacting Yahoo Finance +14.29%
01:16PM  Aethlon Medical Announces Completion of $3.77 Million Registered Direct Offering PR Newswire
08:12AM  Coronavirus Infects Wall Street: Stocks to Gain & Lose Zacks
Jan-21-20 02:40PM  Experimental vaccine stocks jump on concerns about new virus in China MarketWatch +12.14%
Jan-17-20 08:49AM  Aethlon Medical Announces $3.77 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire -25.36%
Dec-17-19 04:18PM  Aethlon Medical Announces Closing of $5 Million Public Offering PR Newswire -6.50%
Dec-13-19 07:00AM  Aethlon Medical Announces Pricing of $5 Million Public Offering PR Newswire -47.85%
Nov-15-19 05:04AM  Here's Why We Worry About Aethlon Medical's (NASDAQ:AEMD) Cash Burn Situation Simply Wall St.
Nov-01-19 04:15PM  Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update PR Newswire -10.00%
Oct-29-19 03:17PM  Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on November 1, 2019 PR Newswire -15.42%
Oct-28-19 07:00AM  AEMD: IDE Approved. Hemopurifier U.S. Clinical Cancer Program On-Deck Zacks Small Cap Research
Oct-14-19 03:55PM  Aethlon Announces Reverse Stock Split PR Newswire
Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. The company is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Champion Christopher OSVP, CAO and ControllerJun 01Option Exercise0.001,491014,667Jun 04 04:23 PM